A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
15
3
2019
medline:
15
3
2019
entrez:
15
3
2019
Statut:
ppublish
Résumé
Haemodialysis (HD) and peritoneal dialysis (PD) are commonly used treatments for the management of patients with end-stage renal disease (ESRD). The costs of managing these patients have grown in recent years with increasing rates of non-communicable diseases, which will adversely impact on national health budgets unless addressed. Currently, there is limited knowledge of the costs of ESRD within the public healthcare system in South Africa. The aim of this study was to examine the direct costs of HD and PD in South Africa from a healthcare provider's perspective. A prospective, observational study was undertaken at a leading public hospital in South Africa. A micro-costing approach was applied to estimate healthcare costs using 46 adult patients with ESRD who had been receiving HD and PD for at least 3 months. The highest proportion of patients (35%) were aged 40-50 years. Patients aged 29-39 years were mostly on HD (28% vs. 21% on PD) while those aged 51-59 years mostly used PD (29% vs. 16% on HD). The average age of patients on HD and PD were 41 and 42 years, respectively. Fixed costs were the principal cost driver for HD ($16,231.45) while variable costs were the principal cost driver for PD (US$20,488.79). The annual cost of HD per patient (US$31,993.12) was higher than PD (US$25,282.00 per patient), even though the difference was not statistically significant (p = 0.816). HD costs more than PD from the provider's perspective. These cost estimates may be useful for carrying out future cost-effectiveness and cost-utility analyses in South Africa.
Sections du résumé
BACKGROUND
BACKGROUND
Haemodialysis (HD) and peritoneal dialysis (PD) are commonly used treatments for the management of patients with end-stage renal disease (ESRD). The costs of managing these patients have grown in recent years with increasing rates of non-communicable diseases, which will adversely impact on national health budgets unless addressed. Currently, there is limited knowledge of the costs of ESRD within the public healthcare system in South Africa.
OBJECTIVE
OBJECTIVE
The aim of this study was to examine the direct costs of HD and PD in South Africa from a healthcare provider's perspective.
METHODS
METHODS
A prospective, observational study was undertaken at a leading public hospital in South Africa. A micro-costing approach was applied to estimate healthcare costs using 46 adult patients with ESRD who had been receiving HD and PD for at least 3 months.
RESULTS
RESULTS
The highest proportion of patients (35%) were aged 40-50 years. Patients aged 29-39 years were mostly on HD (28% vs. 21% on PD) while those aged 51-59 years mostly used PD (29% vs. 16% on HD). The average age of patients on HD and PD were 41 and 42 years, respectively. Fixed costs were the principal cost driver for HD ($16,231.45) while variable costs were the principal cost driver for PD (US$20,488.79). The annual cost of HD per patient (US$31,993.12) was higher than PD (US$25,282.00 per patient), even though the difference was not statistically significant (p = 0.816).
CONCLUSION
CONCLUSIONS
HD costs more than PD from the provider's perspective. These cost estimates may be useful for carrying out future cost-effectiveness and cost-utility analyses in South Africa.
Identifiants
pubmed: 30868410
doi: 10.1007/s41669-019-0124-5
pii: 10.1007/s41669-019-0124-5
pmc: PMC6861399
doi:
Types de publication
Journal Article
Langues
eng
Pagination
631-641Commentaires et corrections
Type : ErratumIn
Références
Prim Care Diabetes. 2009 Aug;3(3):157-64
pubmed: 19640820
J Hum Hypertens. 2017 Jan;31(1):14-21
pubmed: 27306087
Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S3-21
pubmed: 24461728
Am J Manag Care. 2009 Aug;15(8):509-18
pubmed: 19670954
Nephrol Dial Transplant. 2008 Jun;23(6):1982-9
pubmed: 18174268
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):565-578
pubmed: 29032396
J Am Coll Cardiol. 2016 Apr 5;67(13):1507-1515
pubmed: 27150680
Sci Rep. 2016 Jul 27;6:30266
pubmed: 27461186
Hypertension. 2015 Feb;65(2):291-8
pubmed: 25385758
Value Health. 2007 Jan-Feb;10(1):61-72
pubmed: 17261117
Health Res Policy Syst. 2018 Mar 14;16(1):23
pubmed: 29540216
S Afr Med J. 2015 Mar 07;105(4):2681
pubmed: 26294888
Hosp Pract (1995). 2018 Oct;46(4):214-220
pubmed: 30058409
PLoS One. 2017 Apr 18;12(4):e0176041
pubmed: 28419150
Am J Kidney Dis. 2014 Jan;63(1 Suppl):A7
pubmed: 24360288
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
AIDS Res Treat. 2011;2011:562790
pubmed: 21860787
Iran J Kidney Dis. 2010 Oct;4(4):282-4
pubmed: 20852367
Appl Health Econ Health Policy. 2014 Aug;12(4):409-20
pubmed: 25017433
Glob Heart. 2016 Mar;11(1):47-59
pubmed: 27102022
N Engl J Med. 2006 Mar 9;354(10):997-9
pubmed: 16525136
Nephrol Dial Transplant. 2005 Dec;20(12):2587-93
pubmed: 16204281
BMC Public Health. 2014 Aug 12;14:837
pubmed: 25118054
BMC Nephrol. 2015 Apr 21;16:59
pubmed: 25896605
J Am Soc Nephrol. 2012 Mar;23(3):533-44
pubmed: 22302194
Perit Dial Int. 2010 Jan-Feb;30(1):23-8
pubmed: 20056975
BMC Obes. 2015 Oct 13;2:42
pubmed: 26617987
Nat Rev Nephrol. 2013 Oct;9(10):610-22
pubmed: 23958719
Diabetes Metab. 2012 Apr;38(2):102-12
pubmed: 22252014
Perit Dial Int. 2012 May-Jun;32(3):254-60
pubmed: 22641735
S Afr Med J. 2016 Jan 21;106(2):156-9
pubmed: 26821893
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
Front Pharmacol. 2017 Nov 09;8:751
pubmed: 29163151
Healthcare (Basel). 2017 Jul 31;5(3):null
pubmed: 28758959
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):181-7
pubmed: 19402806
J Comp Eff Res. 2017 May 9;:null
pubmed: 28485175
Niger J Clin Pract. 2017 Jun;20(6):670-676
pubmed: 28656920
Nat Rev Nephrol. 2014 Nov;10(11):644-52
pubmed: 25157840
Cost Eff Resour Alloc. 2004 Apr 22;2(1):3
pubmed: 15104792
Health Econ Rev. 2015 Dec;5(1):28
pubmed: 26464023
Expert Rev Anti Infect Ther. 2016 Aug;14(8):777-83
pubmed: 27309846
Am J Kidney Dis. 2008 Mar;51(3):515-23
pubmed: 18295068
Clin Kidney J. 2017 Jun;10(3):363-369
pubmed: 28621342
J Comp Eff Res. 2018 Jul;7(7):661-672
pubmed: 29888972
S Afr Med J. 2017 Sep 22;107(10):836-838
pubmed: 29022524
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
Clin Kidney J. 2018 Feb;11(1):108-122
pubmed: 29423210
Kidney Int. 2011 Dec;80(12):1258-70
pubmed: 21993585
Health Econ. 2009 Apr;18(4):377-88
pubmed: 18615835
Kidney Int Suppl (2011). 2017 Dec;7(3):e1
pubmed: 30681074
J Hypertens. 2011 Mar;29(3):610-8
pubmed: 21157368
J Hypertens. 2014 Mar;32(3):464-72
pubmed: 24445390
Nephrol Dial Transplant. 2013 Oct;28(10):2553-69
pubmed: 23737482
Expert Rev Cardiovasc Ther. 2017 Aug;15(8):639-647
pubmed: 28712328
Value Health Reg Issues. 2016 May;9:8-14
pubmed: 27881266
Afr J AIDS Res. 2008 May;7(1):45-53
pubmed: 25871271